DE69828603D1 - Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittelszur Behandlung von Autoimmunkrankheiten - Google Patents
Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittelszur Behandlung von AutoimmunkrankheitenInfo
- Publication number
- DE69828603D1 DE69828603D1 DE69828603T DE69828603T DE69828603D1 DE 69828603 D1 DE69828603 D1 DE 69828603D1 DE 69828603 T DE69828603 T DE 69828603T DE 69828603 T DE69828603 T DE 69828603T DE 69828603 D1 DE69828603 D1 DE 69828603D1
- Authority
- DE
- Germany
- Prior art keywords
- glycosylceramides
- autoimmune diseases
- preparation
- treatment
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 239000004015 abortifacient agent Substances 0.000 abstract 1
- 231100000641 abortifacient agent Toxicity 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000002491 encephalomyelitis Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Developmental Biology & Embryology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9241297 | 1997-04-10 | ||
JP9241297 | 1997-04-10 | ||
PCT/JP1998/001657 WO1998044928A1 (en) | 1997-04-10 | 1998-04-10 | NKT CELL ACTIVATORS CONTAINING α-GLYCOSYLCERAMIDES |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69828603D1 true DE69828603D1 (de) | 2005-02-17 |
DE69828603T2 DE69828603T2 (de) | 2005-12-29 |
Family
ID=14053712
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69840528T Expired - Fee Related DE69840528D1 (de) | 1997-04-10 | 1998-04-10 | NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten |
DE69828603T Expired - Lifetime DE69828603T2 (de) | 1997-04-10 | 1998-04-10 | Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittels zur Behandlung von Autoimmunkrankheiten |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69840528T Expired - Fee Related DE69840528D1 (de) | 1997-04-10 | 1998-04-10 | NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten |
Country Status (13)
Country | Link |
---|---|
US (2) | US6531453B1 (de) |
EP (2) | EP1520583B1 (de) |
JP (1) | JP3495740B2 (de) |
KR (1) | KR100527950B1 (de) |
CN (2) | CN1222293C (de) |
AT (2) | ATE421881T1 (de) |
CA (1) | CA2286482C (de) |
DE (2) | DE69840528D1 (de) |
ES (2) | ES2318236T3 (de) |
HK (1) | HK1029526A1 (de) |
ID (1) | ID23495A (de) |
TW (1) | TW592703B (de) |
WO (1) | WO1998044928A1 (de) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2318236T3 (es) * | 1997-04-10 | 2009-05-01 | Kyowa Hakko Kirin Co., Ltd. | Agentes activadores de celulas nkt que contienen alfa-glucosilceramidas. |
TW575420B (en) | 1997-09-22 | 2004-02-11 | Kirin Brewery | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides |
FR2792205B1 (fr) * | 1999-04-19 | 2001-07-27 | Inst Nat Sante Rech Med | Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie |
SE0000258D0 (sv) * | 2000-01-27 | 2000-01-27 | A & Science Invest Ab | Pharmaceutical preparation and method for treatment of diabetes |
US20010051156A1 (en) * | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
US20040009594A1 (en) * | 2000-06-06 | 2004-01-15 | Hiro Wakasugi | Method for amplifying natural killer t cells |
AU2001268564A1 (en) * | 2000-06-22 | 2002-01-02 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
US20030003132A1 (en) * | 2000-11-07 | 2003-01-02 | Norie Arai | Mucosal immunomodulator and use thereof |
US7419958B2 (en) | 2001-03-26 | 2008-09-02 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
EP1434859A2 (de) * | 2001-07-25 | 2004-07-07 | New York University | Verwendung von glycosylceramiden als adjuvantien für vakzine gegen infektionen und krebs |
ATE342910T1 (de) * | 2001-08-16 | 2006-11-15 | Daiichi Asubio Pharma Co Ltd | Neues glykolipid, und heilmittel für autoimmunerkrankungen, das dieses als wirkstoff enthält |
JP2005536982A (ja) * | 2001-11-07 | 2005-12-08 | 麒麟麦酒株式会社 | インビトロにおけるt細胞増幅および増幅されたt細胞集団 |
US6911434B2 (en) * | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
FR2839310A1 (fr) * | 2002-05-03 | 2003-11-07 | Pasteur Institut | Nouveau procede de preparation d' alpha-glycosylceramides, nouveaux derives alpha-glycosylceramide et leurs applications |
WO2003105769A2 (en) | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
EP1572114A2 (de) * | 2002-09-27 | 2005-09-14 | Biomira, Inc. | Glycosylceramid-analoga |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
WO2004064820A2 (en) | 2003-01-20 | 2004-08-05 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
NL1022443C2 (nl) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipiden voor verbetering van de samenstelling van de darmflora. |
CA2515396A1 (en) * | 2003-02-14 | 2004-08-26 | Daiichi Suntory Pharma Co., Ltd. | New glycolipids and synthetic method thereof as well as their synthetic intermediates,and synthetic method thereof |
US20040171522A1 (en) * | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US9717754B2 (en) | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
JPWO2004078957A1 (ja) * | 2003-03-03 | 2006-06-08 | 麒麟麦酒株式会社 | 免疫応答の抑制に用いることのできる、α−グリコシルセラミド誘導体と抗原とを提示する樹状細胞 |
US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
US7771726B2 (en) * | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
US20060269524A1 (en) * | 2004-02-19 | 2006-11-30 | Kibun Food Chemifa Co., Ltd. | Composition for nkt cell activation |
EP1576894A1 (de) * | 2004-03-16 | 2005-09-21 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Verwendung von Sphingolipiden zur Behandlung und Prävention von TYP 2 DIABETES, Insulinresistenz und METABOLISCHEN SYNDROMS |
AU2005220692A1 (en) * | 2004-03-16 | 2005-09-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome |
JP2007531768A (ja) * | 2004-03-31 | 2007-11-08 | ニューヨーク・ユニバーシティ | 感染症、癌および自己免疫疾患を治療するための新規な合成c−糖脂質、その合成および使用 |
PT1767216E (pt) | 2004-06-11 | 2012-08-27 | Riken | Fármaco tendo um ligando de células reguladoras contido num lipossoma |
KR101377116B1 (ko) * | 2004-08-27 | 2014-03-24 | 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 | 면역 및 자가면역의 조절제로서의 세라마이드 유도체 |
US8022043B2 (en) * | 2004-08-27 | 2011-09-20 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
CA2578052C (en) * | 2004-09-03 | 2013-08-13 | The University Of Chicago | Methods of activating nkt cells |
WO2006042177A2 (en) | 2004-10-07 | 2006-04-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
CN101031307B (zh) * | 2004-11-02 | 2012-09-05 | 小利兰斯坦福大学托管委员会 | 抑制nkt细胞的制药用途 |
ATE539741T1 (de) | 2004-11-30 | 2012-01-15 | Tno | Sphingolipide bei der behandlung und prävention von hepatischer steatose |
JP5090928B2 (ja) * | 2004-12-28 | 2012-12-05 | ザ ロックフェラー ユニバーシティ | Nkt細胞に対する抗原としての糖脂質及びその類似体 |
US7923013B2 (en) | 2004-12-28 | 2011-04-12 | The Rockefeller University | Glycolipids and analogues thereof as antigens for NKT cells |
PT1848813E (pt) | 2005-01-28 | 2013-07-15 | Scripps Research Inst | Activação de glicolípidos bacterianos de células nkt restritas ao cd1d |
JP5099343B2 (ja) | 2005-03-04 | 2012-12-19 | 独立行政法人理化学研究所 | 環状構造を有する化合物及びその用途 |
JP4909264B2 (ja) * | 2005-04-01 | 2012-04-04 | 独立行政法人理化学研究所 | 経鼻ワクチン |
KR20080021761A (ko) * | 2005-07-01 | 2008-03-07 | 국립 정신.신경센터 총장이 대표하는 일본국 | 당지질 유도체 및 이것을 유효 성분으로 하는 치료제 |
JP2007070311A (ja) * | 2005-09-09 | 2007-03-22 | Gunma Univ | α−ガラクトシルセラミドからなる感染症予防剤及び感染症治療剤 |
US20090117089A1 (en) * | 2005-09-19 | 2009-05-07 | The Rockefeller University | Glycolipids and analogues thereof as antigens for nk t cells |
WO2007050668A1 (en) | 2005-10-25 | 2007-05-03 | Ludwig Institute For Cancer Research | Analogs of alpha galactosylceramide and uses thereof |
US20090048185A1 (en) * | 2005-10-28 | 2009-02-19 | Sachiko Miyake | Therapeutic Drug for Suppressing Functions of NKT Cells Containing Glycolipid Derivative as Active Ingredient |
US20070231344A1 (en) * | 2005-10-28 | 2007-10-04 | The Brigham And Women's Hospital, Inc. | Conjugate vaccines for non-proteinaceous antigens |
US8163705B2 (en) * | 2006-02-28 | 2012-04-24 | Riken | Glycolipid and use thereof |
US8227581B2 (en) | 2006-04-07 | 2012-07-24 | The Scripps Research Institute | Modified α-galactosyl ceramides for staining and stimulating natural killer T cells |
IL178821A0 (en) * | 2006-05-25 | 2007-07-04 | Ilan Yaron | Direct and indirect modulation of composition and structure of cell membrane by ??-glycolipids |
JP5564672B2 (ja) * | 2006-06-30 | 2014-07-30 | ザ スクリプス リサーチ インスティテュート | アジュバント及びその使用方法 |
US8263576B2 (en) * | 2006-08-15 | 2012-09-11 | Mayo Foundation For Medical Education And Research | Non-natural sphingolipid analogs and uses thereof |
KR100868959B1 (ko) * | 2006-12-30 | 2008-11-17 | 재단법인서울대학교산학협력재단 | 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물 |
EP2112930B1 (de) | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation der nkt-zellaktivität mit antigenbeladenen cdid-molekülen |
EP2133326B1 (de) * | 2007-02-22 | 2015-12-23 | Riken | Neues pseudoglycolipid und anwendung davon |
US8916164B2 (en) | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
EP2058011A1 (de) | 2007-11-07 | 2009-05-13 | Wittycell | NKT-Zellen aktivierende, kovalent gebundene Glykolipid-Antigene und/oder Arzneimittel |
EP2060252A1 (de) | 2007-11-19 | 2009-05-20 | Wittycell | Neue Formulierung von Galactosylceramid-Derivaten |
PT2231145E (pt) | 2007-12-05 | 2014-12-23 | Wittycell | Utilização de glicosilceramidas para aumentar a resposta imunitária a antigénios |
EP2272854B1 (de) * | 2008-03-25 | 2015-08-05 | Riken | Neues glykolipid und anwendung davon |
CN102215864A (zh) | 2008-10-08 | 2011-10-12 | 威蒂赛尔公司 | 用于抗流感的疫苗组合物 |
NZ593794A (en) * | 2009-01-08 | 2013-04-26 | Einstein Coll Med | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
JP5669215B2 (ja) | 2010-02-05 | 2015-02-12 | 独立行政法人理化学研究所 | 新規合成糖脂質およびその用途 |
WO2011112889A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY |
EP2647384B1 (de) | 2010-12-02 | 2018-05-23 | Riken | IMMUNTHERAPIE MIT ALLO-NKT-ZELLEN, ZELLEN FÜR DIE IMMUNTHERAPIE MIT UMGEORDNETER aplha KETTE DES T-ZELL REZEPTOR (TCR)-GENS IN GLEICHMÄSSIGE V alpha-J alpha-ANORDNUNG UND LAGERUNG VON NKT-ZELLEN AUS DIESEN ZELLEN |
WO2013162016A1 (ja) | 2012-04-26 | 2013-10-31 | 独立行政法人理化学研究所 | 新規カルバメート糖脂質およびその用途 |
EP2889039B1 (de) | 2012-08-22 | 2017-11-08 | Regimmune Corporation | Präparat zur vorbeugung oder behandlung von typ-1-diabetes |
WO2014053482A1 (en) * | 2012-10-03 | 2014-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists |
US20150283235A1 (en) | 2012-11-05 | 2015-10-08 | Regimmune Corporation | Immune-tolerance inducer |
AU2013349706B2 (en) | 2012-11-21 | 2019-08-22 | Assistance Publique - Hopitaux De Paris | Methods for determining the risk of acute graft versus host disease |
US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
NZ710949A (en) | 2013-02-08 | 2020-02-28 | Vaccinex Inc | Modified glycolipids and methods of making and using the same |
US10307471B2 (en) | 2013-05-02 | 2019-06-04 | National Institute Of Advanced Industrial Science And Technology | Immunity inducer for saccharide antigens |
US20170029454A1 (en) * | 2013-06-28 | 2017-02-02 | The Scripps Research Institute | Nkt cell ligands and methods of use |
EP3111945B1 (de) * | 2014-02-26 | 2021-07-14 | National University Corporation Hokkaido University | Dendritische zellen zur verwendung in der behandlung von herzinfarkt |
WO2017040885A1 (en) | 2015-09-03 | 2017-03-09 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
WO2017163808A1 (ja) | 2016-03-22 | 2017-09-28 | 学校法人慶應義塾 | 化合物又はその塩、ナチュラルキラーt細胞活性化剤、及び医薬組成物 |
WO2017207040A1 (en) | 2016-06-01 | 2017-12-07 | Vib Vzw | ANTI-CANCER THERAPY USING A LEPTIN ANTAGONIST AND AN iNKT-CELL ACTIVATOR |
CN106983760A (zh) * | 2017-05-29 | 2017-07-28 | 南京佰泰克生物技术有限公司 | 一种增强肺腺癌细胞对cik细胞杀伤敏感性的组合物 |
US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
US20230414507A1 (en) | 2020-12-04 | 2023-12-28 | Regimmune Corporation | Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics |
CN114196629B (zh) * | 2021-12-23 | 2024-02-27 | 珠海贝索细胞科学技术有限公司 | 一种高效培养nkt细胞的试剂及其应用和nkt细胞的培养方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK84691D0 (da) * | 1991-05-07 | 1991-05-07 | Karsten Buschard | Visse glycolipider og specifikke catchere for disse til anvendelse ved profylaxe eller terapi af diabetes, og/eller dermed forbundne komplikationer samt anvendelse af saadanne glycolipider til detektion af oe-celle-antistoffer (ica) i et individ og anvendelse af saadanne catchere til detektion af langerhans-oe-celler i pancreas-praeparater |
TW261533B (de) * | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
EP0666268B1 (de) * | 1992-10-22 | 2000-04-19 | Kirin Beer Kabushiki Kaisha | Neues sphingolglycolipid und verwendung davon |
JPH06199884A (ja) * | 1992-12-28 | 1994-07-19 | Nisshin Oil Mills Ltd:The | 新規糖脂質誘導体 |
AU683653B2 (en) * | 1993-04-15 | 1997-11-20 | Kirin Pharma Kabushiki Kaisha | Novel sphingoglycolipid and use thereof |
JPH1045603A (ja) * | 1996-07-30 | 1998-02-17 | Yoshitomi Pharmaceut Ind Ltd | スルファチドを有効成分とするTNF−α産生抑制剤 |
TW555562B (en) * | 1996-12-27 | 2003-10-01 | Kirin Brewery | Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof |
ES2318236T3 (es) * | 1997-04-10 | 2009-05-01 | Kyowa Hakko Kirin Co., Ltd. | Agentes activadores de celulas nkt que contienen alfa-glucosilceramidas. |
-
1998
- 1998-04-10 ES ES04030878T patent/ES2318236T3/es not_active Expired - Lifetime
- 1998-04-10 CN CNB988060884A patent/CN1222293C/zh not_active Expired - Lifetime
- 1998-04-10 CA CA002286482A patent/CA2286482C/en not_active Expired - Lifetime
- 1998-04-10 JP JP54260598A patent/JP3495740B2/ja not_active Expired - Lifetime
- 1998-04-10 DE DE69840528T patent/DE69840528D1/de not_active Expired - Fee Related
- 1998-04-10 WO PCT/JP1998/001657 patent/WO1998044928A1/ja active IP Right Grant
- 1998-04-10 AT AT04030878T patent/ATE421881T1/de not_active IP Right Cessation
- 1998-04-10 DE DE69828603T patent/DE69828603T2/de not_active Expired - Lifetime
- 1998-04-10 EP EP04030878A patent/EP1520583B1/de not_active Expired - Lifetime
- 1998-04-10 AT AT98912758T patent/ATE286735T1/de not_active IP Right Cessation
- 1998-04-10 ES ES98912758T patent/ES2235324T3/es not_active Expired - Lifetime
- 1998-04-10 TW TW087105454A patent/TW592703B/zh not_active IP Right Cessation
- 1998-04-10 CN CNA2005100927032A patent/CN1768759A/zh active Pending
- 1998-04-10 KR KR10-1999-7009253A patent/KR100527950B1/ko not_active IP Right Cessation
- 1998-04-10 ID IDW991170A patent/ID23495A/id unknown
- 1998-04-10 EP EP98912758A patent/EP0988860B1/de not_active Expired - Lifetime
-
1999
- 1999-10-12 US US09/402,785 patent/US6531453B1/en not_active Expired - Fee Related
-
2001
- 2001-01-11 HK HK01100286A patent/HK1029526A1/xx not_active IP Right Cessation
-
2003
- 2003-01-02 US US10/334,861 patent/US6747010B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1768759A (zh) | 2006-05-10 |
KR100527950B1 (ko) | 2005-11-09 |
ATE286735T1 (de) | 2005-01-15 |
AU742253B2 (en) | 2001-12-20 |
EP0988860A1 (de) | 2000-03-29 |
ATE421881T1 (de) | 2009-02-15 |
EP0988860A4 (de) | 2003-09-03 |
ES2235324T3 (es) | 2005-07-01 |
AU6748598A (en) | 1998-10-30 |
EP1520583A3 (de) | 2006-01-25 |
EP0988860B1 (de) | 2005-01-12 |
WO1998044928A1 (en) | 1998-10-15 |
HK1029526A1 (en) | 2001-04-06 |
CN1259872A (zh) | 2000-07-12 |
TW592703B (en) | 2004-06-21 |
ES2318236T3 (es) | 2009-05-01 |
US6531453B1 (en) | 2003-03-11 |
ID23495A (id) | 2000-04-27 |
DE69828603T2 (de) | 2005-12-29 |
JP3495740B2 (ja) | 2004-02-09 |
KR20010006174A (ko) | 2001-01-26 |
EP1520583A2 (de) | 2005-04-06 |
CN1222293C (zh) | 2005-10-12 |
DE69840528D1 (de) | 2009-03-19 |
CA2286482A1 (en) | 1998-10-15 |
EP1520583B1 (de) | 2009-01-28 |
US20030139351A1 (en) | 2003-07-24 |
CA2286482C (en) | 2008-08-05 |
US6747010B2 (en) | 2004-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69828603D1 (de) | Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittelszur Behandlung von Autoimmunkrankheiten | |
DK0513104T3 (da) | Anvendelse af et alfa-tocopherolphosphat eller et af dets derivater til fremstilling af kosmetiske, dermatologiske eller farmaceutiske præparater, og således opnåede præparater | |
BRPI0113042B8 (pt) | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato | |
ATE16191T1 (de) | Stabile salze von s-adenosinylmethionin, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen welche als aktive substanz diese derivate enthalten. | |
UA35567C2 (uk) | Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату | |
HUP0100558A2 (hu) | S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben | |
SE8703066D0 (sv) | Antiseptic composition containing ethyl alcohol and monolaurin | |
TNSN98113A1 (fr) | Procede de preparation de composes utiles pour le traitement de la resistance a l'insuline. | |
ATE426402T1 (de) | Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l | |
ES2124307T3 (es) | Derivados de 3-hidroxipiridin-4-ona como agentes de quelacion. | |
US3363624A (en) | Prophylactic device | |
KR910004191A (ko) | 신질환치료제 | |
ATE157871T1 (de) | Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind | |
DE69001515D1 (de) | Urethan-derivate, ihre herstellung und verwendung als hautbefeuchtendes mittel in kosmetischen und pharmazeutischen zubereitungen zur behandlung trockener haut. | |
AU626743B2 (en) | Therapeutic application of fluoroquinolone derivatives for pneumocystosis | |
TR200103144T2 (tr) | Yeni bileşikler | |
ATE22282T1 (de) | Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen. | |
DE69312512T2 (de) | Etoposid-derivate, ihre herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels | |
ATE147755T1 (de) | Dipeptidderivate und diese als aktive bestandteile enthaltendes prophylaktisches oder therapeutisches mittel gegen knochenkrankheiten | |
EP1291349A4 (de) | Malto-oligosaccharide und deren verwendung | |
KR910002455A (ko) | 아크릴산 유도체를 함유하는 제약 조성물 및 의약으로서 이들의 사용 | |
DE69228235D1 (de) | Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung | |
KR890001555A (ko) | 요산 배설용 조성물 | |
SE8500962D0 (sv) | Nitrodiaryl sulfoxide derivatives, process for their preparation and pharmaceutical and pesticidal compositions containing them as active ingredient | |
JPS6281315A (ja) | 水虫等細菌性皮膚病の治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: KIRIN PHARMA KABUSHIKI KAISHA, SHIBUYA, TOKYO, JP |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP |